 | • レポートコード：MRC2209B010 • 出版社/出版日：Persistence Market Research / 2022年7月14日 • レポート形態：英文、PDF、250ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査レポートは、世界の皮膚科用バイオ製剤市場について調査し、エグゼクティブサマリー、市場概要、主要市場トレンド、主要成功要因、市場背景、新型コロナウイルス感染症の危機分析、需要分析・予測、製品別（インターロイキン（IL）阻害剤、腫瘍壊死因子（TNF）阻害剤）分析、エンドユーザー別（病院薬局、小売薬局、eコマース）分析、地域別（北米、中南米、ヨーロッパ、東アジア、南アジア、オセアニア、中東・アフリカ）分析、市場構造分析、競争分析、仮定、調査手法、以下の構成でまとめております。本書では、Merck and Co. Inc.、Novartis AG、Pfizer Inc.、AbbVie Inc.、Amgen Inc.、AstraZenca、Celgene Corporation、Eli Lilly and Company、Johnson and Johnson（Janssen Biotech Inc.）などの企業情報が含まれています。 ・エグゼクティブサマリー ・市場概要 ・主要市場トレンド ・主要成功要因 ・市場背景 ・新型コロナウイルス感染症の危機分析 ・需要分析・予測 ・世界の皮膚科用バイオ製剤市場規模：製品別 - 皮膚科用インターロイキン（IL）阻害剤の市場規模 - 皮膚科用腫瘍壊死因子（TNF）阻害剤の市場規模 ・世界の皮膚科用バイオ製剤市場規模：エンドユーザー別 - 病院薬局における市場規模 - 小売薬局における市場規模 - eコマースにおける市場規模 ・世界の皮膚科用バイオ製剤市場規模：地域別 - 北米の皮膚科用バイオ製剤市場規模 - 中南米の皮膚科用バイオ製剤市場規模 - ヨーロッパの皮膚科用バイオ製剤市場規模 - 東アジアの皮膚科用バイオ製剤市場規模 - 南アジアの皮膚科用バイオ製剤市場規模 - オセアニアの皮膚科用バイオ製剤市場規模 - 中東・アフリカの皮膚科用バイオ製剤市場規模 ・市場構造分析 ・競争分析 ・仮定 ・調査手法 |
Dermatology Biologics Market: Scope of Report
The latest publication by Persistence Market Research on the global dermatology biologics market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights on current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.
Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers to know the demand for dermatology biologics market products and the quantitative development opportunities during the study period.
The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the dermatology biologics market. Insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the dermatology biologics market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.
Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the dermatology biologics market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.
Key Market Segments
Persistence Market Research’s study on the dermatology biologics market offers information divided into three important segments – product type, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Product Type
Interleukin Inhibitors
Tumor Necrosis Factor Inhibitors
End User
Hospital Pharmacies
Retail Pharmacies
e-Commerce
Region
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa
Key Questions Answered in Report
Which regions will continue to remain the most profitable markets for dermatology biologics over the coming years?
How will changing trends impact the market?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the dermatology biologics market avail themselves the growth opportunities in developed and emerging sectors?
Research Methodology
In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the dermatology biologics market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market, and makes Persistence Market Research’s projections on the growth prospects of the dermatology biologics market are more accurate and reliable.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions & Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Development Trends
4. Key Success Factors
4.1. Key Regulation
4.2. Disease Epidemiology
4.3. Patient Treatment Journey
4.4. Pipeline Assessment
4.5. PESTLE Analysis
4.6. Porters Analysis
4.7. Value Chain Analysis
4.8. Key Promotion Strategies, by Manufacturers
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.1.3. Global Dermatology Market Outlook
5.2. Forecast Factors – Relevance & Impact
5.2.1. Rising Patient Awareness related Initiatives
5.2.2. Increasing Prevalence of Skin Disorder
5.2.3. Growing R&D in Healthcare Sector
5.2.4. Per Patient spending
5.2.5. Increasing Number of Acquisitions in the Key Regions
5.2.6. Rising Collaboration among Key Players
5.2.7. Rising Demand for Biologicals
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue By Product Type
6.1.2. Revenue By End User
6.1.3. Revenue By Region
6.2. 2021 Market Scenario
7. Global Dermatology Biologics Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032
7.1. Historical Market Value (US$ Mn) Analysis, 2017–2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Dermatology Biologics Market Analysis 2017–2021 and Forecast 2022–2032, By Product Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2017–2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product Type, 2022–2032
8.3.1. Interleukin Inhibitors
8.3.2. Tumor Necrosis Factor Inhibitor
8.4. Market Attractiveness Analysis By Product Type
9. Global Dermatology Biologics Market Analysis 2017–2021 and Forecast 2022–2032, By End User
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By End User, 2017–2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022–2032
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. E-Commerce
9.4. Market Attractiveness Analysis By End User
10. Global Dermatology Biologics Market Analysis 2017–2021 and Forecast 2022–2032, by Region
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Analysis By Region, 2017–2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022–2032
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. East Asia
10.3.5. South Asia
10.3.6. Oceania
10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region
11. North America Dermatology Biologics Market Analysis 2017–2021 and Forecast 2022–2032
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
11.3.1. By Country
11.3.1.1. U.S.
11.3.1.2. Canada
11.3.2. By Product Type
11.3.3. By End User
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Product Type
11.4.3. By End User
11.5. Market Trends
11.6. Key Market Participants – Intensity Mapping
11.7. Drivers and Restraints – Impact Analysis
11.8. Country Level Analysis & Forecast
11.8.1. U.S. Dermatology Biologics Market
11.8.1.1. Introduction
11.8.1.2. Market Analysis and Forecast by Market Taxonomy
11.8.1.2.1. By Product Type
11.8.1.2.2. By End User
11.8.2. Canada Dermatology Biologics Market
11.8.2.1. Introduction
11.8.2.2. Market Analysis and Forecast by Market Taxonomy
11.8.2.2.1. By Product Type
11.8.2.2.2. By End User
12. Latin America Dermatology Biologics Market Analysis 2017–2021 and Forecast 2022–2032
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Argentina
12.3.1.3. Mexico
12.3.1.4. Rest of Latin America
12.3.2. By Product Type
12.3.3. By End User
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Product Type
12.4.3. By End User
12.5. Market Trends
12.6. Key Market Participants – Intensity Mapping
12.7. Drivers and Restraints – Impact Analysis
12.8. Country Level Analysis & Forecast
12.8.1. Brazil Dermatology Biologics Market
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Product Type
12.8.1.2.2. By End User
12.8.2. Argentina Dermatology Biologics Market
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Product Type
12.8.2.2.2. By End User
12.8.3. Mexico Dermatology Biologics Market
12.8.3.1. Introduction
12.8.3.2. Market Analysis and Forecast by Market Taxonomy
12.8.3.2.1. By Product Type
12.8.3.2.2. By End User
13. Europe Dermatology Biologics Market Analysis 2017–2021 and Forecast 2022–2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. France
13.3.1.3. Italy
13.3.1.4. Spain
13.3.1.5. UK
13.3.1.6. BENELUX
13.3.1.7. Russia
13.3.1.8. Nordic Countries
13.3.1.9. Rest of Europe
13.3.2. By Product Type
13.3.3. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Product Type
13.4.3. By End User
13.5. Market Trends
13.6. Key Market Participants – Intensity Mapping
13.7. Drivers and Restraints – Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. Germany Dermatology Biologics Market
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Product Type
13.8.1.2.2. By End User
13.8.2. France Dermatology Biologics Market
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Product Type
13.8.2.2.2. By End User
13.8.3. Italy Dermatology Biologics Market
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Product Type
13.8.3.2.2. By End User
13.8.4. Spain Dermatology Biologics Market
13.8.4.1. Introduction
13.8.4.2. Market Analysis and Forecast by Market Taxonomy
13.8.4.2.1. By Product Type
13.8.4.2.2. By End User
13.8.5. U.K. Dermatology Biologics Market
13.8.5.1. Introduction
13.8.5.2. Market Analysis and Forecast by Market Taxonomy
13.8.5.2.1. By Product Type
13.8.5.2.2. By End User
13.8.6. Benelux Union Dermatology Biologics Market
13.8.6.1. Introduction
13.8.6.2. Market Analysis and Forecast by Market Taxonomy
13.8.6.2.1. By Product Type
13.8.6.2.2. By End User
13.8.7. Nordic Countries Dermatology Biologics Market
13.8.7.1. Introduction
13.8.7.2. Market Analysis and Forecast by Market Taxonomy
13.8.7.2.1. By Product Type
13.8.7.2.2. By End User
13.8.8. Russia Dermatology Biologics Market
13.8.8.1. Introduction
13.8.8.2. Market Analysis and Forecast by Market Taxonomy
13.8.8.2.1. By Product Type
13.8.8.2.2. By End User
14. South Asia and Pacific Dermatology Biologics Market Analysis 2017–2021 and Forecast 2022–2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
14.3.1. By Country
14.3.1.1. India
14.3.1.2. Indonesia
14.3.1.3. Malaysia
14.3.1.4. Thailand
14.3.1.5. Rest of South Asia
14.3.2. By Product Type
14.3.3. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product Type
14.4.3. By End User
14.5. Market Trends
14.6. Key Market Participants – Intensity Mapping
14.7. Drivers and Restraints – Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. India Dermatology Biologics Market
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Product Type
14.8.1.2.2. By End User
14.8.2. Indonesia Dermatology Biologics Market
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Product Type
14.8.2.2.2. By End User
14.8.3. Malaysia Dermatology Biologics Market
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Product Type
14.8.3.2.2. By End User
14.8.4. Thailand Dermatology Biologics Market
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast by Market Taxonomy
14.8.4.2.1. By Product Type
14.8.4.2.2. By End User
15. East Asia Dermatology Biologics Market Analysis 2017–2021 and Forecast 2022–2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Product Type
15.3.3. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product Type
15.4.3. By End User
15.5. Market Trends
15.6. Key Market Participants – Intensity Mapping
15.7. Drivers and Restraints – Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. China Dermatology Biologics Market
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Product Type
15.8.1.2.2. By End User
15.8.2. Japan Dermatology Biologics Market
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Product Type
15.8.2.2.2. By End User
15.8.3. South Korea Dermatology Biologics Market
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Product Type
15.8.3.2.2. By End User
16. Oceania Dermatology Biologics Market Analysis 2017–2021 and Forecast 2022–2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
16.3.1. By Country
16.3.1.1. Australia
16.3.1.2. New Zealand
16.3.2. By Product Type
16.3.3. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product Type
16.4.3. By End User
16.5. Market Trends
16.6. Key Market Participants – Intensity Mapping
16.7. Drivers and Restraints – Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. Australia Dermatology Biologics Market
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Product Type
16.8.1.2.2. By End User
16.8.2. New Zealand Dermatology Biologics Market
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Product Type
16.8.2.2.2. By End User
17. Middle East and Africa Dermatology Biologics Market Analysis 2017–2021 and Forecast 2022–2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
17.3.1. By Country
17.3.1.1. Turkey
17.3.1.2. Israel
17.3.1.3. South Africa
17.3.1.4. Rest of Middle East and Africa
17.3.2. By Product Type
17.3.3. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product Type
17.4.3. By End User
17.5. Market Trends
17.6. Key Market Participants – Intensity Mapping
17.7. Drivers and Restraints – Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. Turkey Dermatology Biologics Market
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Product Type
17.8.1.2.2. By End User
17.8.2. Israel Dermatology Biologics Market
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Product Type
17.8.2.2.2. By End User
17.8.3. South Africa Dermatology Biologics Market
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Product Type
17.8.3.2.2. By End User
18. Market Structure Analysis
18.1. Market Analysis by Tier of Companies
18.2. Market Share Analysis of Top Players
18.3. Market Presence Analysis
18.3.1. Regional Footprint by Players
18.3.2. Product Type Footprint by Players
18.3.3. Channel Footprint by Players
19. Competition Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Competition Deep Dive
19.3.1. Merck and Co. Inc.
19.3.1.1. Overview
19.3.1.2. Product Type Portfolio
19.3.1.3. Key Financials
19.3.1.4. SWOT Analysis
19.3.1.5. Key Developments
19.3.1.6. Sales Footprint
19.3.1.7. Strategy Overview
19.3.1.7.1. Marketing Strategy
19.3.1.7.2. Product Type Strategy
19.3.1.7.3. Channel Strategy
19.3.2. Novartis AG
19.3.2.1. Overview
19.3.2.2. Product Type Portfolio
19.3.2.3. Key Financials
19.3.2.4. SWOT Analysis
19.3.2.5. Key Developments
19.3.2.6. Sales Footprint
19.3.2.7. Strategy Overview
19.3.2.7.1. Marketing Strategy
19.3.2.7.2. Product Type Strategy
19.3.2.7.3. Channel Strategy
19.3.3. Pfizer Inc.
19.3.3.1. Overview
19.3.3.2. Product Type Portfolio
19.3.3.3. Key Financials
19.3.3.4. SWOT Analysis
19.3.3.5. Key Developments
19.3.3.6. Sales Footprint
19.3.3.7. Strategy Overview
19.3.3.7.1. Marketing Strategy
19.3.3.7.2. Product Type Strategy
19.3.3.7.3. Channel Strategy
19.3.4. AbbVie Inc.
19.3.4.1. Overview
19.3.4.2. Product Type Portfolio
19.3.4.3. Key Financials
19.3.4.4. SWOT Analysis
19.3.4.5. Key Developments
19.3.4.6. Sales Footprint
19.3.4.7. Strategy Overview
19.3.4.7.1. Marketing Strategy
19.3.4.7.2. Product Type Strategy
19.3.4.7.3. Channel Strategy
19.3.5. Amgen Inc.
19.3.5.1. Overview
19.3.5.2. Product Type Portfolio
19.3.5.3. Key Financials
19.3.5.4. SWOT Analysis
19.3.5.5. Key Developments
19.3.5.6. Sales Footprint
19.3.5.7. Strategy Overview
19.3.5.7.1. Marketing Strategy
19.3.5.7.2. Product Type Strategy
19.3.5.7.3. Channel Strategy
19.3.6. AstraZenca
19.3.6.1. Overview
19.3.6.2. Product Type Portfolio
19.3.6.3. Key Financials
19.3.6.4. SWOT Analysis
19.3.6.5. Key Developments
19.3.6.6. Sales Footprint
19.3.6.7. Strategy Overview
19.3.6.7.1. Marketing Strategy
19.3.6.7.2. Product Type Strategy
19.3.6.7.3. Channel Strategy
19.3.7. Celgene Corporation
19.3.7.1. Overview
19.3.7.2. Product Type Portfolio
19.3.7.3. Key Financials
19.3.7.4. SWOT Analysis
19.3.7.5. Key Developments
19.3.7.6. Sales Footprint
19.3.7.7. Strategy Overview
19.3.7.7.1. Marketing Strategy
19.3.7.7.2. Product Type Strategy
19.3.7.7.3. Channel Strategy
19.3.8. Eli Lilly and Company
19.3.8.1. Overview
19.3.8.2. Product Type Portfolio
19.3.8.3. Key Financials
19.3.8.4. SWOT Analysis
19.3.8.5. Key Developments
19.3.8.6. Sales Footprint
19.3.8.7. Strategy Overview
19.3.8.7.1. Marketing Strategy
19.3.8.7.2. Product Type Strategy
19.3.8.7.3. Channel Strategy
19.3.9. Johnson and Johnson (Janssen Biotech Inc.)
19.3.9.1. Overview
19.3.9.2. Product Type Portfolio
19.3.9.3. Key Financials
19.3.9.4. SWOT Analysis
19.3.9.5. Key Developments
19.3.9.6. Sales Footprint
19.3.9.7. Strategy Overview
19.3.9.7.1. Marketing Strategy
19.3.9.7.2. Product Type Strategy
19.3.9.7.3. Channel Strategy
20. Assumptions and Acronyms Used
21. Research Methodology
Table 01: Global Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032, By Product TypeTable 02: Global Dermatology Biologics Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User
Table 03: Global Dermatology Biologics Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Region
Table 04: North America Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 05: North America Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032, By Product Type
Table 06: North America Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Table 07: Latin America Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 08: Latin America Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032, By Product Type
Table 09: Latin America Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Table 10: Europe Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 11: Europe Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032, By Product Type
Table 12: Europe Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Table 13: South Asia Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 14: South Asia Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032, By Product Type
Table 15: South Asia Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Table 16: East Asia Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 17: East Asia Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032, By Product Type
Table 18: East Asia Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Table 19: Oceania Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 20: Oceania Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032, By Product Type
Table 21: Oceania Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Table 22: Middle East & Africa Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 23: Middle East & Africa Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032, By Product Type
Table 24: Middle East & Africa Dermatology Biologics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User